SOURCE: Brain Sciences. 10 (12) (pp 1-16), 2020. Article Number: 962. Date of Publication: December 2020.
AUTHORS: Yrondi A.; Bennabi D.; Haffen E.; Quelard D.; Samalin L.; Maruani J.; Allauze E.; Pierre D.; Bougerol T.; Camus V.; D’amato T.; Doumy O.; Holtzmann J.; Lancon C.; Moliere F.; Moirand R.; Nieto I.; Richieri R.M.; Horn M.; Schmitt L.; Stephan F.; Genty J.-B.; Vaiva G.; Walter M.; Courtet P.; Leboyer M.; Llorca P.-M.; Marguet S.; Dennis N.; Schaetz D.; El-Hage W.; Aouizerate B.
BACKGROUND: Major depressive disorder (MDD) is among the most common psychiatric disorders. One-third of patients are usually unresponsive to several lines of treatment. This study aimed to describe the FondaMental French cohort of patients with treatment-resistant depression (TRD) and to estimate utility and healthcare resource use outcomes.
METHOD(S): Patients with TRD were evaluated prospectively over four years (baseline, 6, 12, 18, 24, 36 and 48 months) in a real-world clinical setting. Interim analyses focused on the first two consecutive years. Four MDD-related states (major depressive episode (MDE), response, remission, recovery) were defined based on the MADRS (Montgomery-Asberg depression rating scale) and other clinical events. Health status was assessed with the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire. Utility values were estimated as preference measures that the patients assigned to their overall health status.
RESULT(S): This study was based on 252 patients with TRD. The mean utility value by health state was 0.41, 0.63, 0.80, and 0.90, for MDE, response, remission, and recovery, respectively. At baseline, 59% of patients had an MADRS score of at least 28. Their baseline average utility value was lower compared to the other patients (0.43 versus 0.58, p < 0.001). This significant difference persisted at the following visits. The rate of patients in MDEs having at least one hospitalisation for depression or other reasons than depression was generally higher than that in the other health states.
CONCLUSION(S): This study documented patterns in healthcare resource consumption, quality of life, and other characteristics in patients with TRD, both globally and by health state and depression severity.